# Dorsal Root Ganglion Stimulation for Postherpetic Neuralgia: A Pilot Scoping Review of the Current Evidence

## TL;DR

This review explores the use of dorsal root ganglion stimulation to treat postherpetic neuralgia, a chronic pain condition, and finds promising but limited evidence.

## Contribution

The study provides a pilot scoping review of DRG stimulation for PHN, highlighting gaps in current evidence and the need for standardized trials.

## Key findings

- DRG stimulation shows potential for managing PHN but lacks rigorous randomized trials.
- Variability in stimulation techniques and outcomes complicates comparisons.
- Few studies focus exclusively on PHN, with many including mixed-pain populations.

## Abstract

This review synthesizes current evidence regarding the use of dorsal root ganglion (DRG) stimulation, a form of pain neuromodulation, for managing postherpetic neuralgia (PHN), a debilitating chronic neuropathic pain syndrome arising from herpes zoster virus infection. Comprehensive searches across multiple databases (MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library) for studies published from 2010 onward were supplemented by manual reference checks and gray literature review. Inclusion criteria encompassed adults with PHN (pain persisting ≥ three months post-rash onset) treated with DRG stimulation involving varying lead placements and stimulation techniques. Two independent reviewers screened articles and extracted data, resolving disagreements through consensus or a third reviewer, with a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram documenting study selection, resulting in 23 included studies after screening 117 initial references. Extracted data revealed variability in DRG stimulation techniques (percutaneous vs. surgical lead placement) and parameters (tonic, burst, high-frequency), with reported outcomes including pain scores, quality of life, opioid use, and complications. While case series support DRG efficacy for PHN, studies are limited by small sample sizes and a lack of prospective or randomized trials focused exclusively on PHN. Many studies included mixed-pain populations, complicating direct comparisons. Broader neuromodulation evidence suggests DRG may cause fewer paresthesias than spinal cord stimulation (SCS). Some studies indicate DRG may be more effective for other neuropathic pain types than for PHN. This review identifies significant variability and substantial gaps in the literature, notably the absence of rigorous randomized controlled trials and studies focusing solely on PHN, underscoring the need for standardized protocols and targeted clinical trials. Although DRG stimulation shows potential for managing PHN, its comparative effectiveness relative to other pain etiologies warrants further investigation to refine treatment approaches and optimize patient outcomes.